Access to diverse, well-characterized biospecimens remains a challenge in CRC research, slowing biomarker discovery and treatment development. At Boca Biolistics, we provide a vast, research-ready CRC biorepository to accelerate breakthroughs. Facing These Challenges? -Limited Sample Diversity? Global collection spanning ages 20–80 -Need All CRC Stages? Early (~25%), Intermediate (~40%), Advanced (~28%), Metastatic (~6%) -Looking for More Sample Types? 3,000+ FFPE Tumors, 1,200+ NAT, 850+ Histology Slides & more Require Detailed Clinical Data? Every specimen is well-annotated for genomic, proteomic, & histological research Let’s accelerate your research! Explore our biospecimen solutions: www.bocabio.com #ColorectalCancer #CancerResearch #Biospecimens #PrecisionMedicine #Oncology #LifeSciences #BocaBiolistics
关于我们
We are a one-of-a-kind resource built for the future of life science research. BocaBio is a hybrid CRO serving the pharmaceutical, biotech, and IVD industries ISO-certified Biobanx biospecimen inventory ACRP and CCRA-certified clinical research services CLIA-certified and CAP-accredited reference laboratory services We help pharmaceutical and IVD research companies develop tomorrow’s therapies Our biobank, CRO, and reference lab services enable: Pharmaceutical companies to develop novel therapeutic drugs. IVD companies to develop innovative diagnostic technologies Biotech companies to conduct critical research.
- 网站
-
https://www.bocabio.com
Boca Biolistics, LLC的外部链接
- 所属行业
- 生物技术
- 规模
- 11-50 人
- 总部
- Pompano Beach，FL
- 类型
- 私人持股
- 创立
- 2005
- 领域
- Diagnostics CRO、Collection of Human Biological Material for Research、Biorepository、Infectious Disease, Rheumatology, Endocrinology, Oncology, Normal Donors, Cadaveric, all matrices.、Global Clinical Trial、Full Service Reference Laboratory、Oncology、CDx、MDx、Cancer、Cancer Biobank、Cancer Tissue、Trpoical Diseases、Lyme、Tick-Bourne、CAP Laboratory和ISO Biobank
地点
Boca Biolistics, LLC员工
动态
-
Multiple myeloma research faces key hurdles: - Limited Biospecimens – High-quality, diverse samples are hard to source. - Disease Complexity – Variability makes biomarker discovery challenging. - Data Gaps – Robust clinical insights are often missing. - Slow Sample Access – Delays hinder research progress. At Boca Biolistics, we bridge these gaps with: - A global biorepository of diverse, ethically sourced myeloma samples. - Comprehensive clinical datasets for deeper insights. - Streamlined access to accelerate research. This Myeloma Action Month, we stand with researchers, driving discoveries toward better patient outcomes. Let’s innovate together! #MyelomaActionMonth #MultipleMyeloma #ResearchChallenges #BocaBiolistics #AdvancingScience
-
-
The recent NIH update on Lonsurf and Talzenna for patients with TP53 mutations underscores a critical challenge for oncology researchers: how to effectively study and develop treatments for these aggressive cancers. TP53 mutations are present in over 50% of human cancers, often linked to resistance to therapies and poor outcomes. At Boca Biolistics, we understand these challenges firsthand. Our extensive biorepository offers well-characterized oncology biospecimens, including those with TP53 mutations, enabling researchers to: - Access high-quality, clinically annotated tumor samples - Leverage matched plasma, serum, and tissue specimens for biomarker discovery - Streamline preclinical and clinical research with robust biospecimen procurement solutions With precision oncology advancing rapidly, having reliable, well-characterized samples is more crucial than ever. We are committed to supporting researchers in their mission to develop next-generation cancer therapies. #CancerResearch #Oncology #Biospecimens #TP53 #CancerTherapeutics #BocaBiolistics
Although TP53 mutations help drive the growth of most cancers, there are no FDA-approved therapies that target altered p53 proteins. Now a drug combination has shown promise in mice and is being tested in a clinical trial. https://go.nih.gov/3vKdrxj
-
-
Today, on International Women’s Day, we honor the remarkable women driving progress in science, healthcare, and research. From the lab to leadership, women continue to break barriers, innovate, and shape the future of global health. At Boca Biolistics, we are proud to support and collaborate with women researchers, scientists, and healthcare professionals who are making groundbreaking advancements. To all the women making a difference —we see you, we support you, and we celebrate you! Let’s continue to push for equity, inclusion, and innovation in healthcare and research. #IWD2024 #WomenInScience #WomenInHealthcare #BocaBiolistics #EquityInResearch #InternationalWomensDay
-
-
Today is HPV Awareness Day! HPV is a common virus affecting 600 million people globally and is the leading cause of cervical cancer. Early detection and research are crucial in preventing HPV-related diseases. At Boca Biolistics, we support HPV research with high-quality biospecimens, clinical trial support, and assay validation to advance diagnostics, vaccine development, and treatments. Partner with us to drive innovation in HPV prevention and treatment. Contact us today! #HPVAwareness #BocaBiolistics #HPVResearch #CancerPrevention #HealthcareInnovation
-
Heading to Precision Med Tri-Con 2025 from March 11-13 in San Diego? We’d love to connect! Boca Biolistics will be attending, and we're excited to discuss how our expertise in biospecimen solutions, clinical research, and diagnostic development can support your work. Not attending Precision Med Tri-Con? No problem! We'll be in the San Diego area and would be happy to arrange a meeting outside the conference as well. Let’s connect—send us a message or comment below to coordinate! #PrecisionMedTriCon2025 #TriCon2025 #BocaBiolistics #Biotech #ClinicalResearch #Diagnostics
-
-
Understanding the physiological constraints imposed by tumor progression is critical in oncology research. As neoplastic cells proliferate, their metabolic demands often surpass the capacity of the existing vasculature, resulting in hypoxic microenvironments. These conditions activate adaptive mechanisms, such as angiogenesis, metabolic reprogramming, and immune evasion, which contribute to increased malignancy and therapeutic resistance. At Boca Biolistics, we are dedicated to advancing cancer research by providing high-quality, well-characterized biospecimens and comprehensive data solutions. Our extensive repository—comprising over one million biospecimens collected from more than 120 sites across 60 countries—offers researchers access to diverse, clinically relevant samples essential for studying tumor heterogeneity, microenvironmental dynamics, and treatment response. By enabling access to meticulously annotated biospecimens and leveraging robust data analytics, we strive to empower the scientific community in elucidating tumor biology's intricacies and expediting the development of targeted, efficacious cancer therapies.
As tumors grow, they outpace the surrounding blood vessels' ability to provide enough oxygen, a state known as hypoxia. Rather than killing the tumor, however, hypoxia triggers changes in cancer cell metabolism that promote tumor growth and spread. Understanding more about hypoxia in cancer cells may help researchers find better ways of managing the disease. This 2015 image of a mouse model for HER2-positive breast cancer uses an imaging technique called transparent tumor tomography that three-dimensionally visualizes the tumor microenvironment at a single-cell resolution. Hypoxic areas are in green; HER2 proteins in blue; CD31 endothelial cells in red.
-
-
The Podcast is now LIVE! Ahead of the Save Our Sites Conference, our CEO joins the conversation to share insights, industry trends, and what to expect at the event. Don’t miss it—tune in now!?
Join the SOS Team along side Valentin Adia & Sebastien Dhonte to discuss how Clairvest Group Inc. & Boca Biolistics, LLC is working every day to Save Our Sites! Thank you to Clairvest Group Inc. & Boca Biolistics, LLC for being part of our pioneering SOS Alliance.
How is Clarivest & Boca Biolistics are Working to "Save Our Sites"
www.dhirubhai.net
-
On this Presidents' Day, we at Boca Bio honor the visionary leadership of pioneers like George Washington, whose commitment to progress and innovation laid the foundation for our nation. Inspired by this legacy, we remain dedicated to advancing healthcare through our comprehensive biospecimen procurement, clinical research services, and central laboratory testing. Together with our partners, we're driving scientific discovery to bring life-changing diagnostics and therapeutics to patients worldwide. Let's continue to lead with purpose and make a lasting impact on global health.
-
-
This Valentine's Day, we're celebrating the heart of our mission: partnering with you to drive scientific breakthroughs and advance healthcare. Together, our collaboration is the perfect specimen of love, enabling life-changing discoveries that impact patients worldwide. Your innovation and dedication inspire us every day, and we’re grateful to support your journey. Thank you for trusting us as your partner in progress. Happy Valentine's Day! ??
-